PropThink’s End-of-Week Recap
Most Popular - We spent the week in San Francisco for the JP Morgan and Biotech Showcase conferences, which proved invaluable for idea generation, networking, and the solidifying of some … Continue Reading
Read NowRecap
PropThink’s Weekly Healthcare Recap
Most Popular - A catalyst-rich 2013 and a solid financial position for BioMarin should push the stock higher. Since we published this story on Monday, shares of the drug … Continue Reading
Read NowPropThink’s Healthcare Wrap-Up for the Christmas Week
Most Popular - Following the Phase III failure of Oncothyreon’s lead candidate Stimuvax, we see some value remaining in the oncology developer. The company has a few options … Continue Reading
Read NowPropThink’s Biotech and Healthcare Recap
Long Ideas - Happy Holidays from the team at PropThink! Our report on Trius Therapeutics tackled the short thesis, repudiating the focal points of the bear argument. Shares are, … Continue Reading
Read NowA Look at the Week in Healthcare and Biotech
Most Popular - Abbot Labs recorded the first sale of Amitiza in Japan, resulting in a $15M milestone payment to Sucampo on Tuesday. Nevertheless, the thinly-traded equity reacted … Continue Reading
Read NowA Recap of PropThink’s Top Stories this Week
Most Popular - Amarin plans to “go it alone” with its Vascepa launch. Without a large pharma partnership or, better yet, an acquirer, we don’t expect investors to … Continue Reading
Read NowPropThink’s Recap of this Week in Biotech
Most Popular - On Monday, we wrote that MethylGene, a relative unknown in the industry, is poised to climb after a recent financing. While the stock remains flat … Continue Reading
Read Now